Pyrilutamide
Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) which is under development for the treatment of androgenic alopecia (pattern hair loss) and acne.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) which is under development for the treatment of androgenic alopecia (pattern hair loss) and acne. The drug is being developed by Suzhou Kintor Pharmaceuticals. As of February 2025, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne.
The drug was also under development for the treatment of diabetic foot ulcers, but development for this indication was discontinued.
Pharmacodynamics
Pyrilutamide is a selective and high-affinity silent antagonist of the androgen receptor (AR). It has an affinity ( ) of 0.28 nM, relative to 3.1 nM in the case of bicalutamide.
See also
List of investigational acne drugs List of investigational hair loss drugs GT-20029 (AR-PROTAC) Clascoterone (Winlevi; Breezula; CB-03-01)
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370576885 under CC BY-SA 4.0; modifications have been made.